The FDA has approved tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and pertuzumab (Perjeta) as a front-line maintenance therapy for adults with unresectable, locally advanced, or metastatic HER2-positive breast cancer following induction treatment. This marks a significant step up for tucatinib, which was previously only approved as a second-line option since 2020.

The approval is backed by the randomized, double-blind phase 3 HER2CLIMB-05 trial (654 patients), which showed the tucatinib-based regimen reduced the risk of disease progression or death by 35.9% versus placebo. Experts note that while this is a meaningful escalation option post-induction, better biomarkers are still needed to identify which patients truly need more intensive therapy.

By the Numbers:

• 24.9 months — median PFS in the tucatinib arm
• 16.3 months — median PFS in the placebo arm
• 35.9% reduction in risk of disease progression or death (HR = 0.64)
• 42.3% of tucatinib patients experienced grade 3+ adverse events vs. 24.4% in the control arm

Why it matters: This FDA approval offers a chemotherapy-free maintenance strategy that targets HER2-positive tumors from multiple angles, potentially prolonging disease control for patients who have already responded to induction therapy — a meaningful advance in a space where many patients still progress despite initial benefit.